Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Nirmala-Sitharaman"

7 News Found

Industry’s reaction to Union Budget 2024-25
Policy | February 02, 2024

Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry


G20 Health Minister’s Meeting concludes in Gandhinagar, Gujarat
Policy | August 21, 2023

G20 Health Minister’s Meeting concludes in Gandhinagar, Gujarat

Global Initiative on Digital Health launched at the G2O Health Minister’s Meeting


Budget 2023-24: Industry welcomes focus on medical research and pharma innovation
Policy | February 02, 2023

Budget 2023-24: Industry welcomes focus on medical research and pharma innovation

It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047


Economic Survey 2022-23: Industry sector witness growth of 4.1%
Policy | February 01, 2023

Economic Survey 2022-23: Industry sector witness growth of 4.1%

The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021


Budget 22-23: Healthcare sector applauds focus on mental health
News | February 01, 2022

Budget 22-23: Healthcare sector applauds focus on mental health

A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook


Foreign Direct Investment in pharma grows at rapid pace: Eco Survey
News | January 31, 2022

Foreign Direct Investment in pharma grows at rapid pace: Eco Survey

In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21


Union Budget 2022-23 : Medtech expects incentives, GST exemptions and custom duty rationalisation
Equipment | January 30, 2022

Union Budget 2022-23 : Medtech expects incentives, GST exemptions and custom duty rationalisation

Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player